Curaleaf Holdings, Inc. Q3 2025 Earnings Recap

CURA.TO Q3 2025 November 6, 2025

Get alerts when CURA.TO reports next quarter

Curaleaf Holdings reported a modest revenue increase to $320 million in Q3 2025, driven by stable domestic performance and strong international growth, while achieving enhanced margins and maintaining a healthy cash position.

Earnings Per Share Beat

$-0.09 vs $-0.10 est.

+10.7% surprise

Revenue Beat

446022284 vs 441325256 est.

+1.1% surprise

Market Reaction

1-Day -14.21%

5-Day -2.74%

30-Day -5.49%

See CURA.TO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue grew 2% sequentially, with international segment up 12% sequentially and 56% year-over-year.
Adjusted gross margins improved to 50%, reflecting a 115 basis point increase.
Achieved $69 million in adjusted EBITDA, with a 22% margin despite headwinds from international operations.
Strong cultivation improvements led to average flower potency exceeding 30% for the first time.
Closed a $100 million revolving credit line to improve financial flexibility and reduce debt obligations.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CURA.TO on AllInvestView.

Next Q1 2026